Vadimezan

Vadimezan
Systematic (IUPAC) name
(5,6-Dimethyl-9-oxo-9H-xanthen-4-yl)-acetic acid
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 117570-53-3
ATC code None
UNII 0829J8133H Y
Synonyms ASA404, DMXAA
Chemical data
Formula C17H14O4 
Mol. mass 282.29 g/mol
SMILES eMolecules & PubChem
 Y(what is this?)  (verify)

Vadimezan or ASA404 (originally DMXAA)[1] is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.[2]

Contents

Clinical trials

Non-small cell lung cancer

Vadimezan has been studied in combination with chemotherapy in at least two Phase II trials for advanced non-small cell lung cancer (NSCLC) and has shown survival extensions of around 5 months when compared to chemotherapy alone (14.0 months compared to 8.8 months).[3] [4] In April 2008, a Phase III trial started. In March 2010 the phase III trial of use as a first line therapy for NSCLC gave poor results.[5] Initerim results on another phase III trial as second-line therapy for NSCLC are due later in 2010 with the trial due to complete in 2011. In Nov 2010 the 2nd trial also gave poor interim results.[6]

Other cancers

As of February 2009 it is being studied for the treatment of prostate cancer[4] and HER2-negative metastatic breast cancer.[1][7]

History

ASA404 was discovered by Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre at the University of Auckland in New Zealand.[7] It was licensed to Antisoma in 2001. Novartis acquired the worldwide rights for it in 2007 and it is being developed by Antisoma and Novartis.[4][7]

References

  1. ^ a b "New Zealand drug tested for breast-cancer fight". New Zealand Herald. 14 February 2009. http://www.nzherald.co.nz/nz/news/article.cfm?c_id=1&objectid=10556717. Retrieved 2009-02-13. 
  2. ^ ASA404, A Novel Cancer Agent, Begins Pivotal Trial To Explore New Approach In Treating Lung Cancer, The Leading Cause Of Cancer Death, Medical News Today, 14 Apr 2008
  3. ^ MJ McKeage et al. (2008). "Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer". Br J Cancer 99 (12): 2006–12. doi:10.1038/sj.bjc.6604808. PMC 2607218. PMID 19078952. http://www.nature.com/bjc/journal/v99/n12/abs/6604808a.html. 
  4. ^ a b c ASA404 Vascular Disrupting Agent for Solid Tumours, drugdevelopment-technology.com
  5. ^ http://www.genengnews.com/news/bnitem.aspx?name=78979622 "Antisoma’s Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial"
  6. ^ "Antisoma and Novartis Ditch ASA404 After Second Phase III NSCLC Trial Bombs". 11 Nov 2010. http://www.genengnews.com/gen-news-highlights/antisoma-and-novartis-ditch-asa404-after-second-phase-iii-nsclc-trial-bombs/81244220/. 
  7. ^ a b c "ASA404 to be developed in breast cancer". Antisoma. 12 February 2009. http://www.antisoma.com/asm/media/press/pr2009/2009-02-12/. Retrieved 2009-02-13.